Natco obtains FDA nod for generic Lonsurf
Generic Lonsurf is indicated primarily for the treatment of colorectal cancer.
Natco recently received the Food and Drug Administration’s approval for Tipiracil Hydrochloride and Trifluridine tablets, which is the generic of Taiho Oncology’s Lonsurf.
Natco said it believes it is one of the first-to-tile for the product and may be eligible for a 180-day exclusivity at the time of launch.
Lonsurf is indicated primarily for the treatment of colorectal cancer.
[Read more: Natco receives FDA nod for 2 generics]
Lonsurf had a market value of $211 million during the 12 months ending December 2022, per IQVIA.
[Read more: Natco, Breckenridge obtain FDA nod for generic Kyprolis]